DBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin Peanut
DBV Technologies reçoit 6 M€ | CFNEWS
Joint press release FNSEA, CONFAGRICOLTURA, DBV CAP reform, A timely agreement At the eve of the Trilogue of the 30th April, P
DBV Technologies S.A. (DBVT) Stock Price, Quote & News - Stock Analysis
DBV Technologies Announces Expansion of Clinical Program of Viaskin Peanut for the Treatment of Peanut Allergy
Doubleview Gold Corp (DBV) Stock Message Board | InvestorsHub
EX-99.1
News | DBV Technologies
DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results | DBVT Stock News
DBV Technologies Update
New Verdict Issued in Elinescu-Wladow Case | bridge | ♧ Neapolitan Club
DBV Technologies S.A. (DBVT) Stock Price, Quote & News - Stock Analysis
Viaskin Peanut Patch: Lasting Response After Three Years | SnackSafely.com
DBV, Developers of Patch Therapies for Allergies to Peanuts, Milk and Eggs, to Lay off 2/3 of Staff | SnackSafely.com
Peanut Allergy Pipeline, FDA Approvals, Clinical Trials
PRESS RELEASE Karsten Hell is new management board member ...
DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document
Dbv technologies : L'essai clinique sur le patch anti-allergies de DBV va pouvoir reprendre aux Etats-Unis - BFM Bourse
DBV Technologies S.A. (DBVT) Stock Price, Quote & News - Stock Analysis
DBV Technologies a reçu les commentaires de la FDA sur les éléments de conception des études
DBV Announces Promising 2-Year Results from Ongoing Viaskin “Peanut Patch” Toddler Study | SnackSafely.com
DBV Technologies (@DBVTechnologies) / X
EX-99.1
DBV Technologies: share price falls as Xolair receives green light in the USA -February 19, 2024 at 06:00 am EST | MarketScreener
Actualités - AEF Online
